Correlation Between Cullinan Oncology and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Cullinan Oncology and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cullinan Oncology and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cullinan Oncology LLC and SAB Biotherapeutics, you can compare the effects of market volatilities on Cullinan Oncology and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cullinan Oncology with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cullinan Oncology and SAB Biotherapeutics.

Diversification Opportunities for Cullinan Oncology and SAB Biotherapeutics

0.61

Correlation Coefficient

Cullinan Oncology  SAB Biotherapeutics

Poor diversification

The 3 months correlation between Cullinan and SAB is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Cullinan Oncology LLC and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Cullinan Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cullinan Oncology LLC are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Cullinan Oncology i.e., Cullinan Oncology and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Cullinan Oncology and SAB Biotherapeutics

Given the investment horizon of 90 days Cullinan Oncology LLC is expected to generate 0.28 times more return on investment than SAB Biotherapeutics. However, Cullinan Oncology LLC is 3.52 times less risky than SAB Biotherapeutics. It trades about -0.32 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about -0.12 per unit of risk. If you would invest  1,239  in Cullinan Oncology LLC on December 3, 2024 and sell it today you would lose (390.00) from holding Cullinan Oncology LLC or give up 31.48% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Cullinan Oncology LLC  vs.  SAB Biotherapeutics

Cullinan Oncology LLC

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cullinan Oncology LLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Cullinan Oncology and SAB Biotherapeutics

The main advantage of trading using opposite Cullinan Oncology and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cullinan Oncology position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Cullinan Oncology LLC and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.